Cargando…
342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
BACKGROUND: Guidelines recommend use of tocilizumab (TCZ), an inhibitor of pro-inflammatory IL-6 signaling, for hospitalized patients with progressive severe or critical Coronavirus disease 2019 (COVID-19). The incidence of infectious complications following the use of TCZ for COVID-19 has not been...
Autores principales: | Warner, Adam, Abbas, Mujahed, Avner, Benjamin S, Flynn, Thomas E, Walroth, Todd A, Jagger, Brett W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690531/ http://dx.doi.org/10.1093/ofid/ofab466.543 |
Ejemplares similares
-
563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020) -
400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital
por: Usiak, Shauna, et al.
Publicado: (2020) -
342. Clinical Utility of a Next Generation Sequencing Test for Pathogen Detection in Pediatric Central Nervous System Infections
por: Ramchandar, Nanda, et al.
Publicado: (2020) -
34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE
por: Fusar-poli, Paolo, et al.
Publicado: (2018) -
553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)